Mebrouk, S
Clin Orthop Relat Res 1984:303-11
Disclosures: Isaac Benque: Nothing to Disclose, Arielle Klepper: Nothing to Disclose, Michael Li: Nothing to Disclose, Gerardo Rubio Monroy: Nothing to Disclose, Swathi Kari: Nothing to Disclose, Melawit Tekeste: Nothing to Disclose, Javier Castro: Nothing to Disclose, Briton Lee: Nothing to Disclose, Mandana Khalili: gilead sciences: Grant/Research Support, GSK pharmaceuticals: Consultant, Intercept pharmaceuticals: Grant/Research Support, Gilead Sciences Inc: Consultant, Jennifer Price: Nothing to Disclose, Emily Perito: Mirum: Consultant, Ultragenyx: Consultant, BridgeBio: Consultant, Amagma: Consultant, Mirum: Grant/Research Support, Albireo: Grant/Research Support, Gilead: Grant/Research Support, Dicerna: Grant/Research Support, Sandy Feng: Nothing to Disclose, Jacquelyn Maher: Nothing to Disclose, Jennifer Lai: Nestle Nutrition Institute: Grant/Research Support, Novo Nordisk: Consultant, Genfit: Consultant, Boehringer Ingelheim: Advisor, POSULD Team: Nothing to Disclose, Joseph DeRisi: Nothing to Disclose, Michele Tana: Nothing to Disclose 2406 PERFORMANCE OF URSODEOXYCHOLIC ACID RESPONSE SCORE IN PREDICTING TREATMENT RESPONSE IN A SINGLE UNITED STATES COHORT Ana Marenco-Flores 1 Leandro Sierra 1 Romelia Barba 2 Denisse Rubio-Cruz 1 Daniela Goyes 3 John Esli Medina Morales 4 Tamara Kahan 5 Alan Bonder 1 Vilas Patwardhan 1 , 1 Beth Israel Deaconess Medical Center, 2 Texas Tech University, 3 Yale School of Medicine, 4 Rutgers New Jersey Medical School, 5 Besth Israel Deaconess Medican Center Background: The Ursodeoxycholic Acid Response Score (URS) predicts UDCA therapy response in primary biliary cholangitis (PBC) patients after 12 months of treatment
10.1111/pim.12087 6 ColleyD
